View More Recent Stories

Dec 23, 2016 04:51PM U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy
Nov 7, 2016 07:32AM Biogen (BIIB), Ionis Pharma (IONS) Announce SPINRAZA Phase 3 Met Primary Endpoint in Later-Onset SMA
Nov 7, 2016 07:30AM Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy
Oct 28, 2016 07:38AM Biogen (BIIB) Announces U.S. FDA, EMA Acceptance of Nusinersen Regulatory Applications
Oct 28, 2016 07:30AM Biogen’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA
Oct 8, 2016 10:00AM New Data Presented at World Muscle Society Congress Support Potential Benefit of Investigational Treatment Nusinersen in Spinal Muscular Atrophy
Oct 6, 2016 09:22AM Pre-Open Stock Movers 10/06: (ALQA) (SCYX) (ZUMZ) Higher; (ALNY) (TWTR) (MDCO) Lower (more...)
Sep 26, 2016 07:52AM Biogen (BIIB), Ionis (IONS) Announce Completion of Nusinersen NDA Rolling Submission as SMA Treatment
Sep 26, 2016 07:30AM Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy
Aug 1, 2016 07:34AM Biogen (BIIB), Ionis (IONS) Announce Nusinersen Phase 3 Met Primary Endpoint in Infantile-Onset SMA
Aug 1, 2016 07:30AM Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy
View More Recent Stories